MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.080
-0.030 (-2.70%)
Aug 5, 2026, 2:57 PM EDT - Market open
MaxCyte Employees
MaxCyte had 91 employees as of December 31, 2025. The number of employees decreased by 23 or -20.18% compared to the previous year.
Employees
91
Change (1Y)
-23
Growth (1Y)
-20.18%
Revenue / Employee
$354,802
Profits / Employee
-$429,879
Market Cap
115.69M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 91 | -23 | -20.18% |
| Dec 31, 2024 | 114 | -29 | -20.28% |
| Dec 31, 2023 | 143 | 18 | 14.40% |
| Dec 31, 2022 | 125 | 41 | 48.81% |
| Dec 31, 2021 | 84 | 19 | 29.23% |
| Mar 31, 2021 | 65 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Neuronetics | 658 |
| Quanterix | 450 |
| Outset Medical | 310 |
| AVITA Medical | 226 |
| CVRx, Inc. | 223 |
| Rapid Micro Biosystems | 171 |
| Quantum-Si incorporated | 145 |
| Owlet | 114 |
MXCT News
- 15 days ago - MaxCyte enters technology license partnership with Genentech - TheFly
- 15 days ago - MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development - GlobeNewsWire
- 20 days ago - MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 - GlobeNewsWire
- 6 weeks ago - VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
- 3 months ago - MaxCyte reports Q1 EPS (4c), consensus (9c) - TheFly
- 3 months ago - MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M - TheFly
- 3 months ago - MaxCyte Earnings Call Transcript: Q1 2026 - Transcripts
- 3 months ago - MaxCyte Earnings release: Q1 2026 - Filings